Status
Conditions
Treatments
About
The aim of this study is to detect effect of allopurinol supplementation in pediatric patients with dilated cardiomyopathy.
Full description
DCM as a serious cardiac disorder in which structural or functional abnormalities of the heart muscle can lead to substantial morbidity and mortality owing to complications such as heart failure and arrhythmia Among patients with heart failure (HF), elevated serum uric acid levels and increased oxidative stress have been associated with increased mortality, implicating xanthine oxidase as a possible therapeutic target Xanthine oxidase (XO), a superoxide-generating enzyme, is up regulated in animals (6,7) and in humans with heart failure. Acute administration of the XO inhibitor allopurinol improves the mechanical efficiency of the failing heart ), whereas oxygen consumption paradoxically decreases. Direct XO inhibition in cardiac muscle leads to increased force generation by the myofilaments at any given level of activator calcium(10).
Allopurinol, an inhibitor of xanthine oxidase, may be a novel therapeutic agent for HF. Allopurinol reduces uric acid levels, prevents acute gout, and acts as an anti oxidant, which could be beneficial among HF patients(5)
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
1 - children (1-16) year's age with impaired left ventricular systolic function due to dilated cardiomyopathy, who attend pediatric cardiology unit 2-children attend to pediatric cardiology out patient clinic in Assiut university children hospital 3-children with no allergic reaction from allopurinol
Exclusion criteria
100 participants in 1 patient group
Loading...
Central trial contact
Ghada seif elnasr mohamed, M.B.B.CH.; Amr Mohamed kotb, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal